BMS invests in cell therapy
Bristol Myers Squibb Co has stepped up its commitment to cell therapies with plans to spend $1.5 billion to acquire a Cambridge, Massachusetts biotech which is developing a medicine to reprogramme the immune system and treat autoimmune diseases. Orbital’s lead product, OTX-201, is an in vivo chimeric antigen receptor (CAR) T cell therapy that is being developed using ribonucleic acid (RNA) technology. The preclinical product consists of a circular RNA that encodes a CAR which targets cells expressing CD19, a B cell specific antigen.
